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Abstract
Background: Drug-induced liver injury (DILI) has been a public, economic and pharmaceutical issue for many years.
Enormous effort has been made for discovering and developing novel biomarkers for diagnosing and monitoring both
clinical and preclinical DILI at an early stage, though progress has been relatively slow. Additionally, herb-induced liver injury
is an emerging cause of liver disease because herbal medicines are increasingly being used worldwide. Recently, circulating
microRNAs (miRNAs) have shown potential to serve as novel, minimally invasive biomarkers to diagnose and monitor
human cancers and other diseases at early stages.
Methodology/Principal Findings: In order to identify candidate miRNAs as diagnostic biomarkers for DILI, miRNA
expression profiles of serum and liver tissue from two parallel liver injury Sprague-Dawley rat models induced by a
compound (acetaminophen, APAP) or an herb (Dioscorea bulbifera, DB) were screened in this study. The initial screens were
performed on serum using a MicroRNA TaqMan low-density qPCR array and on liver tissue using a miRCURY LNA
hybridization array and were followed by a TaqMan probe-based quantitative reverse transcription-PCR (qRT-PCR) assay to
validate comparison with serum biochemical parameters and histopathological examination. Two sets of dysregulated
miRNA candidates in serum and liver tissue were selected in the screening phase. After qRT-PCR validation, a panel of
compound- and herb- related serum miRNAs was identified.
Conclusions/Significance: We have demonstrated that this panel of serum miRNAs provides potential biomarkers for
diagnosis of DILI with high sensitivity and specificity.
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Introduction
Drug-induced liver injury (DILI) is the most frequent reason for
the withdrawal of approved drugs from the market and for the
rejection of potential drugs in discovery and development phases.
DILI directly results in human suffering and health care
expenditure [1,2]. Reports of DILI arouse fear and skepticism in
the public regarding the actions of both the pharmaceutical
industry and the FDA [3].
Herbal medicines are increasingly used worldwide, and people
usually regard them as ‘‘dietary supplements’’ without side effects
[4,5,6]. With an increasing awareness among healthcare profes-
sionals of their potential harmful effects, associated side effects of
herbal medicines, including hepatotoxicity, are increasingly
reported [4,5,6]. In a prospective study from the United States,
single or multiple dietary supplements were implicated in 9% of
drug-induced liver injury cases [7]. Studies from Asian countries
suggest that 20–55% of drug-induced liver injury is related to
herbs [8]. As a kind of DILI, there is a growing body of evidence
suggesting that herb-induced liver injury is an emerging cause of
liver disease [4,5,6].
Acetaminophen (APAP), known as paracetamol outside the
United States, is the most widely used pharmaceutical analgesic
and antipyretic agent across the world and is usually considered to
be safe and benign. However, APAP overdose may lead to
hepatotoxicity and is potentially fatal [9]. The herb of Dioscorea
bulbifera (DB), as a traditional Chinese medicine, is widely
distributed in Asia and used to treat various diseases, such as
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years has demonstrated that DB can cause severe hepatotoxicity in
both clinical and preclinical studies [12,13]. Hepatotoxicity
induced either by chemical agents or by herbal medicines has
become a public health issue and has limited the clinical
applications of such compounds.
Numerous efforts have been made to discover and develop
biomarkers that can indicate hepatic disease at early stages. Blood
biomarkers in conventional liver function assays, including alanine
aminotransferase (ALT) activity, aspartate aminotransferase (AST)
activity, alkaline phosphatase (ALP) activity, total bilirubin,
gamma-glutamyl transferase (GGT) activity and bile acids, are
widely used by physicians to noninvasively evaluate liver injury
[3,14]. However, this set of conventional biomarkers cannot fully
meet the needs of clinical diagnosis. For example, serum ALT
activity is also associated with muscle necrosis [15,16]. Serum AST
activity is associated with liver toxicity, but also can be elevated in
association with heart and skeletal muscle injury [15,17].
Additionally, serum ALT and AST do not always correlate well
with histomorphological results [3]. Although other non-routine
predictive biomarkers of hepatotoxicity have received attention
recently, they have not been used for routine human clinical
testing for various reasons [18].
Recently, the discovery of microRNAs (miRNAs) has paved a
new avenue for both the diagnosis and treatment of cancers and
other diseases [19,20]. miRNAs are endogenous non-coding
RNAs that are 19–24 nucleotides in length and play an important
role in physiological and pathological processes [21]. The
expression profiles of highly stable and readily detected circulating
miRNAs in serum, plasma, and other body fluids herald immense
potential for their use as novel minimally invasive biomarkers in
diagnosing and monitoring human cancers [19,20]. In the process
of searching circulating miRNA as diagnostic biomarkers,
scientists have developed two working models to identify and
refine differentially expressed miRNAs in disease samples com-
pared to control samples [22]: 1) To directly select certain
miRNAs as candidates based on the literature data mining. For
example, Laterza et al. [23] and Zhang et al. [24] directly selected
certain miRNAs as candidate diagnostic biomarkers for liver
injury based on the literature data mining. However, as this
approach has no initial high-throughput screening phase, the
identified biomarkers might be incomprehensive. 2) To employ
some high-throughput techniques (e.g., miRNA microarray,
Solexa sequencing and MicroRNA TaqMan low-density arrays)
to screen for differentially expressed circulating miRNAs. These
high-throughput techniques are widely applied in the initial
screening phase and are superior to the existing low-throughput
techniques such as northern blotting and cloning [22]. In the
validation phase, quantitative real-time PCR (qPCR) methodolo-
gies have been widely applied in assessing the low level of certain
serum miRNAs in individual samples [25,26]. For instance, Wang
et al. [27] employed miRNA microarray to screen for differentially
expressed circulating miRNAs in the initial screening phase.
However, because microarray and Solexa sequencing are based on
sequencing and oligonucleotide hybridization, respectively, the
results sometimes do not correlate well with the data of qPCR
assay, which is based on the technique of PCR. Thus, the different
techniques utilized between initial screening phase and validation
phase may result in biased results. To avoid this limitation, some
scientists employed an alternative approach which use qPCR
based screening techniques (e.g., MicroRNA TaqMan low-density
arrays) to identify candidate miRNAs in the initial screening phase
[28,29]. Because the mechanisms of ‘‘MicroRNA TaqMan low-
density arrays’’ are same as those of qRT-PCR assay used in the
validation phase, the selected candidate miRNAs may be more
accurate. Therefore, we employed this approach in present study.
Besides, compared with the relative quantification method used in
previous studies [23,24,27], the absolute quantification strategy we
used could enables us to visualize the actual concentrations of
circulating miRNAs much more accurately [20,30].
In the present study, we employed two parallel classic DILI
animal models, which were induced by a compound (APAP) and
an herb (DB) respectively, and assessed the serum miRNA
expression profiles in these two model groups. Our results
demonstrate that a new panel of serum miRNAs (miR-122,
miR-192 and miR-193) could have the potential to serve as
sensitive, specific and noninvasive biomarkers for the diagnosis of
DILI.
Methods
Animals and animal models
Male 6-week-old Sprague-Dawley rats, which were obtained
from the SIPPR-BK Experimental Animal Co., Ltd. (Shanghai,
China), were housed in an air-conditioned room with 12/12 h
light/dark cycles and were acclimated to the laboratory for 1 week
before any experiments were performed with them. Standard rat
chow and water were available ad libitum. This study was
approved by the Ethical Committee of China Pharmaceutical
University, Nanjing University, and Laboratory Animal Manage-
ment Committee of Jiangsu Province (Approval ID: 2110682). All
of the animal experiments were conducted in compliance with the
standard ethical guidelines and under the control of the Ethical
Committees mentioned above.
APAP (ACROS Organics, New Jersey, USA) in 0.5%
carboxymethylcellulose sodium (0.5% CMC-Na) solution was
administrated once by oral gavage at 1,600, 800 and 400 mg/kg
body weight as described previously [31]. DB water extract in
0.5% CMC-Na solution was administrated once by oral gavage at
the doses of 70, 35 and 16 g/kg body weight according to previous
description [12] and our validation studies. The vehicle group was
administrated with 0.5% CMC-Na solution by oral gavage. For
serum miRNA TLDA analysis, serum samples from the vehicle
group, 1,600 mg/kg body weight APAP and 70 g/kg body weight
DB water extract treatment group were collected at 24 h (n=10
per group). At the same time point (24 h after administration),
serum and liver tissue samples from the vehicle group, control
group, 1,600, 800 and 400 mg/kg body weight APAP and 70, 35
and 16 g/kg body weight DB water extract treatment groups were
collected for serum miRNA dose-dependent analysis (n=6 per
dose per group) and liver tissue miRNA array analysis (n=3 per
dose per group). Serum samples from the vehicle group, control
group, 1,600 mg/kg body weight APAP and 70 g/kg body weight
DB water extract treatment group were collected at 3 h, 6 h, 12 h,
24 h, 2 d, 4 d and 7 d after administration for time-dependent
analysis (n=6 per time point per group).
Blood chemistry
Whole blood samples were centrifuged at 3,000 rpm for 10 min
at 4uC about 2 hours after collection at room temperature. Serum
samples were transferred into a new tube and stored at 270uC.
We used the Olympus AU1000 (Olympus, Japan) automated
biochemical analyzer to measure serum biochemical parameters,
including ALT and AST, according to the manufacturer’s
instructions.
Serum miRNAs as Biomarkers for DILI
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37395Histopathological examination
Liver biopsy samples for histomorphological evaluation were
fixed immediately in 10% neutral-buffered formalin (100 mL 37%
aqueous solution of formaldehyde, 4.0 g NaH2PO4, and 6.5 g
Na2HPO4 per liter), embedded in paraffin, sectioned into 5-mm
thick slices, mounted on poly(L-lysine)-treated slides, stained with
hematoxylin and eosin, and examined by light microscopy. In our
studies conducted to support biomarker qualification, we followed
guidelines set by the Society of Toxicologic Pathology on the
performance of histopathological evaluations. These guidelines
included internal peer review.
Liver RNA isolation and microarray analysis
Total RNA including miRNA from the vehicle group and 2
DILI model groups (n=3 per group) were harvested using TRIzol
(Invitrogen, Carlsbad, CA, USA) and the RNeasy mini kit
(Qiagen, Valencia, CA, USA) according to manufacturer’s
instructions. After being subjected to RNA measurement on the
Nanodrop instrument (the A260/A280 ratio should be close to 2.0
and the A260/A230 ratio should be more than 1.8), 1 mg RNA
from each sample was labeled using the miRCURY
TM Hy3
TM/
Hy5
TM Power labeling kit and hybridized on the miRCURY
TM
LNA (locked nucleic acid) Array v14.0 (Exiqon, Vedbaek,
Denmark). Scanning was performed with the Axon GenePix
4000B microarray scanner. GenePix pro V6.0 was used to read
the raw intensity of the image. The intensity of green signal was
calculated after background subtraction and the median value of
four replicated spots of each probe on the same slide had been
calculated. The approach applied for estimating the background of
a spot is to select an area near each spot and after identifying the
background pixels within this area; the background estimate of the
spot is then taken as the sample median of these pixels. We used
the median normalization method to obtain ‘‘normalized data’’;
normalized data=(foreground-background)/median with the me-
dian being the 50% quantile of microRNA intensity that was
greater than 50 in all samples after background correction. All
data is MIAME compliant and that the raw data has been
deposited in ArrayExpress, Gene Expression Omnibus (Accession
Number: E-MEXP-3364).
Serum miRNA expression profile analysis
The expression levels of miRNA in serum were profiled by
stem-loop RT-PCR-based Rodent MicroRNA TaqMan low-
density arrays (TLDA) (Applied Biosystems, Foster City, CA,
USA). Comprehensive coverage of rodent miRNA species in
Sanger miRBase v15 was enabled across a two-card set of
TaqMan Array Rodent MicroRNA Cards (Card A v2.0 and Card
B v3.0). Serum miRNA collected from 2 DILI groups and the
vehicle group (pooling, volume=10 ml and n=10 per group)
were isolated using the mirVana miRNA Isolation Kit (Applied
Biosystems, Foster City, CA, USA). RT-PCR reactions were
performed according to the manufacturer’s instructions. Briefly,
3 ml total RNA from each sample was reverse transcribed using
the TaqMan miRNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA) in combination with Megaplex
RT Primers (Rodent Pool Set v3.0) in a total volume of 7.5 ml. The
RT cycling conditions were 40 cycles of 16uC for 2 min, 42uC for
1 min and 50uC for 1 sec followed by 85uC for 5 min and a 4uC
hold. Pre-amplification was performed using TaqMan PreAmp
Master Mix and Megaplex PreAmp Primers (Rodent Pool Set
v3.0) (Applied Biosystems, Foster City, CA, USA). Briefly, 2.5 mlo f
the Megaplex RT products were mixed with 2.5 ml of Megaplex
PreAmp Primers and 12.5 ml TaqMan PreAmp Master Mix in a
25-ml PCR reaction. The pre-amplification cycling conditions
were 95uC for 10 min, 55uC for 2 min and 72uC for 2 min
followed by 12 cycles of 95uC for 15 sec and 60uC for 4 min and
followed by 99.9uC for 10 min and a 4uC hold. The pre-amplified
cDNA was diluted with 0.16TE (pH 8.0) to 100 ml, and 9 mlo f
diluted cDNA was used in each plate for real-time PCR reactions.
Quantitative real-time PCR was performed on an Applied
BioSystems 7900HT thermocycler using the manufacturer’s
recommended cycling conditions; cycle threshold (CT) values were
calculated with the accompanying SDS software v2.3 (Applied
Biosystems, Foster City, CA, USA). The relative amount of each
miRNA to an internal control was calculated by using the
equation 2
2DCT, in which DCT=C T miRNA2CTU 6 .
Quantitative Reverse Transcriptional PCR (qRT-PCR)
analysis of individual miRNAs
Assays to quantify mature miRNAs in liver tissue were
conducted using a Taqman miRNA PCR kit (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s instruc-
tions. Briefly, 1 mg of total RNA was reverse-transcribed to cDNA
using AMV reverse transcriptase (TaKaRa, Dalian, China) and
looped anti-sense primers. The mixture was incubated at 16uC for
15 min, 42uC for 60 min and 85uC for 5 min to generate a library
of miRNA cDNAs. Real-time PCR was subsequently performed
using an Applied Biosystems 7300 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) and a standardized
protocol. In each assay, 1 mL of cDNA was used for amplification.
The reactions were incubated in a 96-well optical plate at 95uC for
5 min followed by 40 cycles consisting of a 15 s interval at 95uC
and a 1 min interval at 60uC. After the reactions were completed,
the CT values were determined using the default threshold settings.
Because U6 RNA and 5S rRNA are degraded in serum samples
and a consensus housekeeping miRNA is lacking for qRT-PCR
analysis of serum miRNAs, we normalized miRNA concentration
to serum volume. Briefly, total RNA was extracted from 100 mL
serum with a 1-step phenol/chloroform purification protocol. In
brief, 100 mL serum was mixed with 200 mL acid phenol, 200 mL
chloroform, and 300 mL diethylpyrocarbonate-treated water. The
mixture was vortexed vigorously and incubated at room temper-
ature for 15 min. After phase separation, the aqueous layer was
mixed with 1.5 volumes of isopropyl alcohol and 0.1 volumes of
3 M sodium acetate (pH 5.3). This solution was stored at 220uC
for 1 h. The RNA pellet was collected by centrifugation at
16,0006 g for 20 min at 4uC. The resulting RNA pellet was
washed once with 75% ethanol and dried for 10 min at room
temperature. Finally, the pellet was dissolved in 20 mLo f
ribonuclease-free water and stored at 280uC until further analysis.
A hydrolysis probe-based qRT-PCR assay was conducted as
previously described [25]. We calculated the absolute concentra-
tions of target miRNAs from calibration curves developed with
corresponding synthetic miRNA oligonucleotides (Figure S2 and
Table S5).
Statistical analysis
Statistical analysis was performed with SPSS software (version
18). Data are presented as means and standard deviation, two-
tailed student’s t-test was used to determine the statistical
differences and P-values,0.05 were considered statistically signif-
icant. Hierarchical clustering analysis was performed using
Multiexperiment Viewer, MeV version 4.7 software (http://
www.tm4.org/mev/). The hybridization intensity of each miRNA
was median centered, both gene tree and sample tree were
clustered, the distance metric was Manhattan Distance, and the
linkage method was complete linkage clustering.
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To obtain DILI-specific miRNA expression profiles of both
serum and liver tissue, we employed a strategy using TLDA
analysis for serum and hybridization array analysis for liver tissue.
Next, we validated the candidate miRNAs as diagnostic biomark-
ers for DILI on time- and dose-dependent levels in 2 parallel rat
DILI models (Figure 1).
Serum biochemical parameters and histopathological
examination results from animal models
Blood chemistry was analyzed in all serum samples collected.
Rat serum samples taken 24 h after administration of APAP and
DB for miRCURY
TM LNA microarray and TLDA analysis
showed a significant (P-value,0.05) elevation of ALT and AST
levels compared with the vehicle serum samples (Table S1).
Individually, the ALT and AST levels in each serum sample were
5 times greater than the average limit of normal. This set of serum
biochemical parameters correlated strongly with the degree of
tissue injury observed through histopathological examination.
These results showed that the 2 DILI animal models were
successfully established.
Serum miRNA profiles in rat DILI models explored by
TLDA
The Rodent MicroRNA TaqMan low-density arrays covered all
rodent miRNA species in Sanger miRBase v15. The serum
miRNA expression profiles revealed by TLDA varied across all
three groups. Compared with the vehicle group, 42 serum
miRNAs were upregulated and 60 were downregulated (fold
change .5o r,0.2) in the 2 DILI model groups (Table S2).
Correlation and scatter plot analysis revealed that the correlation
coefficients between rat DILI model groups and the vehicle group
were low; the R values were 0.5608 and 0.4400 for the APAP-
treated group and DB-treated group, respectively (Figure 2A and
2B). As expected, the correlation coefficient between the 2 DILI
model groups was much higher with R values as high as 0.8237
(Figure 2C). The top 10 upregulated and downregulated serum
miRNAs are highlighted in Figure 2D. These results demonstrated
that a set of candidate miRNAs dysregulated in serum could be
used as potential diagnostic biomarkers for DILI.
Liver tissue miRNA profiles in rat DILI models explored by
microarray hybridization
miRCURY LNA
TM microRNA arrays contain more than
1,700 capture probes, covering all miRNAs annotated in miRBase
14.0 and all viral microRNAs related to rat species. The 2 DILI
model groups showed 12 miRNA species that were commonly
dysregulated in 2 DILI model groups compared to the vehicle
group with a mean fold change .1.3 or ,0.77 and a P-
value,0.05 (Table S3). For the visualization of differentially
expressed miRNAs, a heat map was generated using MeV version
4.7 software. The result showed 3 samples from each group
clustered in the same tree and a distinct separation of the 2 DILI
model groups from the vehicle group. As expected, the 2 DILI
model groups clustered in their own tree and clustered together
before clustering with the vehicle group (Figure S1). These results
suggested that a set of dysregulated liver tissue miRNAs could
classify injured liver samples induced by different drugs.
Figure 1. Overview of the experimental strategy.
doi:10.1371/journal.pone.0037395.g001
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qRT-PCR assay
By individual TaqMan qRT-PCR analysis of dysregulated
serum miRNAs uncovered by serum TLDA and dysregulated liver
tissue miRNAs uncovered by microarray hybridization in primary
screening, 6 serum miRNAs, including miR-122, miR-192, miR-
193, miR-200a, miR-21 and miR-29c, exhibited a high correlation
with primary screening results. Among this set of serum miRNAs,
miR-122, miR-192 and miR-193 presented a significant change in
both DILI model groups within the threshold of a fold change
.10 and P-value,0.05 (Table 1). Besides, validation of the
dysregulated liver miRNAs by qRT-PCR showed good correlation
with the microarray hybridization results (Table S4). Based on
these validation results, a set of extremely and stably dysregulated
candidate miRNAs, which could serve as potential diagnostic
biomarkers for DILI, were identified.
Time- and dose-dependent analysis of serum miRNAs
compared with serum biochemical parameters and
histopathological examination results
In the time-dependent analysis of the serum miRNAs miR-122,
miR-192 and miR-193, all of these serum miRNAs exhibited an
ascending trend 3 h after administration in both DILI model
groups (fold change .2.0); while serum biochemical parameters
(e.g., ALT and AST) remained at baseline levels (fold change
,1.5). At 6 h after administration, the concentration of these 3
serum miRNAs had risen rapidly (fold change .10.0), while serum
biochemical parameters changed slightly (fold change ,2.0). The
concentration of serum miR-122 peaked at 12 h after adminis-
tration (fold change .100.0), while serum biochemical parameters
showed a limited change (fold change ,3.0). Meanwhile, the
concentration of the other 2 serum miRNAs changed by a greater
degree than serum biochemical parameters (Figure 3A, 3B, 3C,
3D and 3E). The concentration of these 3 serum miRNAs showed
a rapid reduction at 2 d after administration, and generally
returned to baseline levels from 4 d after administration with a P-
Figure 2. Analysis of serum miRNA expression profiles explored by TLDA. (A) Correlation and scatter plot analysis of relative miRNAs
expression levels in APAP group and vehicle group; (B) Correlation and scatter plot analysis of relative miRNAs expression levels in DB group and
vehicle group; (C) Correlation and scatter plot analysis of relative miRNAs expression levels in DB group and APAP group; In Panel A, B and C, the
relative expression levels of each miRNA to an internal control was calculated by using the equation 2
2DCT610
7, in which DCT=C T miRNA2CTU 6 . The
CT value of ‘‘Undetectable’’ was calculated as 40. (D) Top10upregulatedanddownregulatedserummiRNAsdetectedbyTaqManlow-densityqPCRarray.
Fold change of treated/vehicle was calculated by using the equation 2
2DDCT,i nw h i c hDDCT=(C Tm i R N A 2CTU 6 ) DILI group2(CTm i R N A 2CTU 6 ) vehicle group.A n d
serum miRNAs were ranked by the fold change of the group with the largest upregulated fold (n=10 per group, pooling).
doi:10.1371/journal.pone.0037395.g002
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Serum biochemical parameters displayed a similar fashion to the 3
serum miRNAs (Figure 3D and 3E). In histomorphological
examination, ballooning degeneration appeared in central vein
area 3 h after APAP administration, centrilobular necrosis turned
out at 6 h and became heavier at 12 h. Hydropic degeneration
appeared at 3 h after DB administration, followed by spotty and
focal necrosis at 6 and 12 h. The histomorphological changes
displayed a recovering manner from 2 d after administration
(Figure 3F). The changes in both serum miRNAs and biochemical
parameters correlated well with the results of histomorphological
examination. More importantly, serum miRNA levels are
apparently much more sensitive than biochemical parameters
are to the administered drugs.
In the dose-dependent analysis of the serum miRNAs miR-122,
miR-192 and miR-193, miR-122 showed extremely high sensitiv-
ity in both 2 DILI model groups (fold change .50.0), while serum
biochemical parameters (e.g., ALT and AST) displayed only mild
sensitivity (fold change ,20.0) in the high-dose group. All 3 serum
miRNAs demonstrated better sensitivity than serum biochemical
parameters in the middle- and low-dose group, but serum miR-
122 was much more sensitive than biochemical parameters
(Figure 4A, 4B, 4C, 4D and 4E). In histomorphological
examination, APAP low-dose photomicrograph shown hydropic
degeneration, the middle- and high-dose photomicrographs
demonstrated submassive and massive necrosis, respectively. DB
low-dose photomicrograph shown hydropic degeneration, the
middle- and high-dose photomicrographs demonstrated mild and
severe focal necrosis, respectively (Figure 4F). The changes in both
serum miRNAs and biochemical parameters correlated well with
the results of histomorphological examination.
The results of these analyses revealed both time- and dose-
dependent characteristics of the candidate miRNAs (miR-122,
miR-192 and miR-193) as potential diagnostic biomarkers for
DILI.
Discussion
Although the discovery and development of new biomarkers for
DILI diagnosis has been regarded as an important issue by the
public, the FDA, pharmaceutical industries and research institu-
tions for many years, discovery of sensitive, specific, and
noninvasive biomarkers remains at an early stage [3,18,32].
Fortunately, since 2008, stable miRNAs have been detected in
serum, plasma, urine, saliva and other body fluids, and the
expression profiles of these circulating miRNAs have potential as
biomarkers for novel and minimally invasive diagnosis and
monitoring of human cancers and other diseases including DILI
[19,20,24,27]. One of these works carried out by Wang et al. [27]
directed to the same problem by using different approaches. We
have compared both the methodologies and the results between
this work and the present one as follows. 1) First of all, we
Table 1. qRT-PCR validation of dysregulated serum miRNAs in TLDA results.
miRNAs APAP group DB group
Fold change P-value Fold change P-value
rno-miR-122 54.62 0.00112 255.12 0.00103 significant
##
rno-miR-192 16.79 0.00016 24.80 0.00179 significant
##
rno-miR-193 50.75 0.00005 46.35 0.00008 significant
##
rno-miR-29c 6.03 0.00048 6.77 0.00009 non-significant
rno-miR-21 2.74 0.16797 6.50 0.00055 non-significant
rno-miR-200a 1.86 0.14240 1.83 0.06708 non-significant
rno-miR-183 Assay not linear
rno-miR-101a Assay not linear
rno-miR-101b Assay not linear
rno-miR-1188-5p Assay not linear
rno-miR-133b Assay not linear
rno-miR-327 Assay not linear
rno-miR-380 undetectable in serum
rno-miR-187 undetectable in serum
rno-miR-206 undetectable in serum
rno-miR-292-3p undetectable in serum
rno-miR-183* unchecked
rno-miR-455* unchecked
rno-miR-33* unchecked
rno-miR-22* unchecked
rno-miR-31* unchecked
rno-miR-200c* unchecked
rno-miR-543* unchecked
##: Fold change.10 and P-value,0.05 (n=3).
(The selection of dysregulated serum miRNAs was based on the threshold: the absolute value of DDCT.4 in TLDA results. Raw data was presented in Table S2.).
doi:10.1371/journal.pone.0037395.t001
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37395Figure 3. Time-dependent analysis of serum miRNAs compared with biochemical and histopathological parameters. (A) Serum miR-
122 expression levels; (B) Serum miR-192 expression levels; (C) Serum miR-193 expression levels; (D) Biochemical parameter: serum ALT levels; (E)
Biochemical parameter: serum AST levels. The absolute concentrations of target miRNAs were calculated by referring to calibration curves developed
with corresponding synthetic miRNA oligonucleotides. The data were presented as the means 6 S.D. and student’s t-test was used to determine the
statistical significance of differences between vehicle group and other groups (*, P-values,0.05 versus vehicle; * *, P-values,0.01 versus vehicle; * * *,
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induced by a compound (APAP) or an herb (DB), rather than by a
single DILI animal model in previous study [27]. The serum
miRNA expression profiles of these two model groups were
supposed to be more specific to DILI. And the results of
correlation and scatter plot analysis supported this assumption
well (Figure 2). Beside, among the three serum miRNAs as
potential diagnostic biomarker for DILI explored in rat models in
present study, miR-122 and miR-192 was also validated in plasma
of mice models by Wang et al. [27]. This result indicate that
circulating miRNAs (whether in serum or in plasma) as potential
diagnostic biomarkers for DILI have across-species characteristic
as well. In addition, similar results generated via different
approaches by these two independent studies makes the conclusion
P-values,0.001 versus vehicle, n=6). (F) Histopathological examination results, stained with hematoxylin and eosin, and examined by light
microscopy, 2006. Ballooning degeneration appeared in central vein area 3 h after APAP administration, centrilobular necrosis turned out at 6 h and
became heavier at 12 h. Hydropic degeneration appeared at 3 h after DB administration, followed by spotty and focal necrosis at 6 and 12 h. The
histomorphological changes displayed a recovering manner from 2 d after administration.
doi:10.1371/journal.pone.0037395.g003
Figure 4. Dose-dependent analysis of serum miRNAs compared with biochemical and histopathological parameters. (A) Serum miR-
122 expression levels; (B) Serum miR-192 expression levels; (C) Serum miR-193 expression levels; (D) Biochemical parameter: serum ALT levels; (E)
Biochemical parameter: serum AST levels; The absolute concentrations of target miRNAs were calculated by referring to calibration curves developed
with corresponding synthetic miRNA oligonucleotides. The data were presented as the means 6 S.D. and student’s t-test was used to determine the
statistical significance of differences between vehicle group and other groups (*, P-values,0.05 versus vehicle; * *, P-values,0.01 versus vehicle; * * *,
P-values,0.001 versus vehicle, n=6). (F) Histopathological examination results, stained with hematoxylin and eosin, and examined by light
microscopy, 2006. APAP low-dose photomicrograph shown hydropic degeneration, the middle- and high-dose photomicrographs demonstrated
submassive and massive necrosis, respectively. DB low-dose photomicrograph shown hydropic degeneration, the middle- and high-dose
photomicrographs demonstrated mild and severe focal necrosis, respectively.
doi:10.1371/journal.pone.0037395.g004
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miRNA in serum were profiled by stem-loop RT-PCR-based
TLDA, which mechanisms are same as those of qRT-PCR assay
used in the validation phase. Therefore, the selection on candidate
miRNAs would be more accurate than other initial high-
throughput screening techniques, such as solexa sequencing and
microarray based on the techniques of sequencing and oligonu-
cleotide hybridization, respectively. While hybridization micro-
arrays were applied in plasma miRNAs profiling by Wang et al.
[27]. 3) For analyzing individual miRNAs, instead of the relative
quantification method used in previous study [27], we applied
TLDA and calculated the absolute concentration of target
miRNAs by referring to the calibration curves developed with
corresponding synthetic miRNA oligonucleotides (Figure S2 and
Table S5). 4) In previous study presented by Wang et al. [27], the
relative expression levels of miRNAs showed an ascending trend at
1 and 3 hours after administration with one single drug. In
addition to that, we carried out a time-dependent analysis from
3 hours to 7 days after administration with two drugs indepen-
dently. The concentration of candidate miRNAs demonstrated not
only an ascending trend but also a return to baseline levels
following the time (Figure 3). Beyond confirming the early reports,
our study demonstrates that a panel of serum miRNAs implicated
in compound- and herb-induced liver injury has potential
diagnostic value during the development of DILI.
Changes in the serum miRNA profile after drug overdose may
reflect a complex tissue-injury pattern [27]. In this study, by
employing two parallel rat DILI models, DILI-specific miRNA
expression profiles in serum and liver tissue were explored by
TLDA (v.3.0) and miRCURY
TM LNA array (v.14.0), respectively.
The results of correlation and scatter plot analysis supported the
assumption that serum miRNA expression profiles of these two
model groups were supposed to be more specific to DILI (Figure 2).
Among 102 aberrantly expressed serum miRNAs (Fold change .5
or ,0.2), 61 displayed the same trend of expression alteration in 2
parallel rat DILI models. Although a significant number of
miRNAs in serum were greatly dysregulated, only 12 miRNA
species in liver tissue were commonly dysregulated in 2 DILI
model groups compared to the vehicle group with a mean fold
change .1.3 or ,0.77 and a P-value,0.05 detected by
hybridization. This result was confirmed by TaqMan probe-based
qRT-PCR validation. However, the liver tissue miRNA profiles
could distinguish the different drug-treated groups clearly in
cluster analysis (Figure S1), similar to the application of miRNA
profiles in cancer classification [33,34]. This result suggested that
certain liver tissue miRNA profiles could serve as biomarkers for
classifying the liver injury induced by different drugs. However,
the utility of this type of analysis may be diminished by its
invasiveness.
The panel of miRNAs explored in this study all showed
decreased expression levels in liver tissue but increased expression
levels in serum samples in both parallel rat DILI models (Table 1
and Table S4). ALT activity in the liver is about 3,000 times that
of serum activity and the release of ALT from damaged liver cells
increases observed ALT activity in the serum [14]. The finding
same may be true of miRNAs. The liver-specific miR-122, for
example, is over 1,000 times more abundant in 0.1 g liver tissue
than in 0.1 mL serum (Figure S3). Although direct leakage of
cellular miRNAs into the blood is not common under normal
circumstances, it still occurs under conditions of tissue damage or
cell apoptosis. Passive leakage from broken cells and tissues is a
process that does not require energy. During tumor metastasis or
chronic inflammation, tissues or cells at the primary site may break
up, thereby releasing miRNAs [22]. Therefore, it is possible to
hypothesize that miRNAs in DILI enter the circulation similarly to
ALT. Although miRNAs within the panel were abundant in liver
tissue (Table S6) and miR-122 was considered liver-specific
[24,35,36], the liver specificity of other 2 miRNA species in this
panel need further analysis.
The panel of aberrantly expressed serum miRNAs (miR-122,
miR-192 and miR-193) all exhibited time- and dose-dependent
characteristics. Previously, plasma miR-122 and miR-192 had
been reported increased linearly from 1 to 3 hours and displayed
dose-dependent manner after APAP overdosing in mice. However,
by prolonging the observation window up to 7 days after
administration with two drugs (APAP and DB) independently in
rats, the concentration of 3 serum miRNAs all demonstrated not
only an ascending trend but also a return to basal levels following
the time and displayed dose-dependent characteristics in two
classical DILI rat models. Serum biochemical parameters
displayed similar manners to the 3 serum miRNAs and the
changes in both serum miRNAs and biochemical parameters
correlated well with the features of histomorphological examina-
tion (Figure 3 and Figure 4). Owing to the preanalytical steps
which could affect miRNA detection and quantification, only
miRNAs that are extremely up- or downregulated would be
suitable as clinical biomarkers [37]. The 3 miRNAs within the
panel were all extremely upregulated and, therefore, suitable as
potential clinical DILI diagnosis biomarkers. Given that circulat-
ing miR-122 was previously reported as a DILI biomarker, the
results from the strategies in this study indicate that there is a set of
serum miRNAs highly related to DILI. Among them, circulating
miR-122 had been reported as liver-specifically conserved across
species [24,35,36] and has been applied to diagnosis of various
liver diseases in clinical studies, including hepatocellular carcino-
ma (HCC) [38,39,40], hepatitis B virus (HBV) infection [24,39],
cirrhosis [38] and alcohol- and chemical-related hepatic diseases
[24,27]. Besides, unlike ALT and AST, miR-122 has no
association with muscle disorders [24]. Unfortunately, this
approach has its own disadvantages; circulating miR-122 could
not serve as a biomarker to distinguish these different liver
diseases. Once an elevated circulating miR-122 level has been
detected, a physician cannot make a judgment about what the
specific liver disease(s) is/are using this information alone. Patients
with circulating miR-122 elevation might be infected by HBV
and/or present HCC and/or be stimulated by alcohol abuse
rather than drug overdosing. However, employing a miRNA
expression panel instead of an individual miRNA as a biomarker
represents a rational option to circumvent the current limitations
in using miRNAs for DILI diagnosis [41]. If DILI-specific
miRNAs within the panel were all aberrantly expressed in the
same time, a physician could more easily and accurately judge
whether patients have DILI. In order to identify DILI-specific
serum miRNAs released from drug-injured liver tissue rather than
from other organs or other hepatic injuries, such as viral-induced
hepatic injury or hepatic cancer, we intend to perform large-scale
tests of hepatic toxicants and different species of model animals to
solve this problem. Moreover, in the validation phase, the
candidate miRNAs as potential biomarkers for DILI diagnosis
were selected from the miRNAs that were dysregulated in both 2
DILI groups (listed in bold characters in Table S2). Since the
selected miRNAs are common in both groups, they can not
discriminate APAP group from DB group. Future studies may be
necessary to directly compare the differentially expressed miRNAs
between APAP group and DB group.
Contemporary hepatotoxicity biomarker discovery efforts
focused on marker proteins or metabolites from animal or human
body fluids, from animal tissue extracts/supernatants or from
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because of their low-throughput nature [18]. Although progress in
proteomics and metabolomics has led to the development and
high-throughput use of mass spectrometry (MS) and nuclear
magnetic resonance (NMR), technologies that have the potential
to identify unknown proteins in plasma and urine samples, such
assays are expensive and labor-intensive, which hinders their
widespread application in clinical diagnosis [18,32,41]. The
enzyme-linked immunosorbent assay (ELISA) can be performed
in a high-throughput manner and is suitable for the detection of
diagnostic antigens, but its detection sensitivity is greatly depen-
dent on antibody affinities [18,32,41]. As circulating miRNAs may
be ideal biomarker candidates for various cancers and other
diseases, great attention has been devoted to the discovery of liver
disease-related miRNA biomarkers [27]. Advantages of miRNAs
as biomarkers include noninvasiveness, stability in body fluids,
lower complexity, no post-processing modification, a tissue-
restricted expression profile, synthetic high-affinity ‘‘capture’’
reagent and ‘‘amplifiable’’ signals [20,27,41].
In summary, serum miR-122, miR-192 and miR-193 constitute
a new panel for compound- and herb-induced liver injury
diagnosis. To conclude that this panel of miRNAs is a diagnostic
biomarker for DILI, cross-species validation, screens of additional
hepatotoxicants and clinical trials need to be conducted in the
future. Nevertheless, the panel of miRNAs uncovered in the
present study provides potential biomarkers for diagnosis of DILI
with high sensitivity and specificity.
Supporting Information
Figure S1 Hierarchical clustering analysis of commonly dysreg-
ulated liver miRNAs explored by microarray hybridization. 12
liver miRNA species that were commonly dysregulated in 2 DILI
model groups compared to the vehicle group with a mean fold
change .1.3 or ,0.77 and a P-value,0.05 were applied to
clustering analysis. The hybridization intensity of each miRNA
was median centered, both gene tree and sample tree were
clustered, the distance metric was Manhattan Distance, and the
linkage method was complete linkage clustering. Rows represented
miRNA species, and columns represented the samples from
vehicle group and 2 DILI model groups. Color areas indicated
relative expression levels of each miRNA compared with median
expression level (red, above the median level; green, below the
median level; and black, close to the median level). The
dendrogram displayed a clear separation of not only 2 DILI liver
samples from the vehicle liver samples but also APAP-treated liver
samples from DB treated liver samples (n=3).
(TIF)
Figure S2 Calibration curves of serum miRNA qRT-PCR
analysis. (A) Calibration curve of miR-122; (B) Calibration curve
of miR-192; (C) Calibration curve of miR-193. Synthetic miRNAs
oligonucleotides of known concentrations were reverse-transcribed
and amplified (n=3).
(TIF)
Figure S3 miRNA expression levels in serum and liver tissue of
control group. (A) miR-122 expression levels; (B) miR-192
expression levels; (C) miR-193 expression levels. The volume of
liver was converted by the equation: volume (L)=weight
(mg)4density (mg/dL)410 (dL/L). Ratio: miRNA concentration
in liver versus in serum (n=3).
(TIF)
Table S1 Serum biochemical parameters of rat model serum
samples.
(DOC)
Table S2 Dysregulated serum miRNAs in 2 DILI groups
comparing with vehicle group.
(DOC)
Table S3 Dysregulated liver tissue miRNAs in 2 DILI groups
compared with vehicle group.
(DOC)
Table S4 qRT-PCR validation of dysregulated liver miRNAs in
microarray hybridization results.
(DOC)
Table S5 Sequences of synthetic mature miRNAs.
(DOC)
Table S6 Top 20 abundant miRNA species of liver tissue in
microarray hybridization results.
(DOC)
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